RxDoctor Payments DataLook up a doctor →

Arthur Lee, MD

Interventional Cardiology · Gainesville, FLNPI 1063447977

Payments from drug & device makers

$1,950,355in general payments, 2019–2025

Across 2,374 payments — averaging $821.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$548K
  • Amgen$478K
  • Boehringer Ingelheim$206K
  • Bard Peripheral Vascular, Inc.$127K
  • Lilly USA, LLC$124K
  • Inari Medical, Inc.$58K
  • plus $409K from 54 others
$16,915in research payments, 2019–2025

Across 12 payments — averaging $1409.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cook Research Incorporated$11K
  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$6K

What the payments were for

  • Consulting fees$162,9949%
  • Speaking & faculty fees$1,326,76475%
  • Travel & lodging$173,33310%
  • Food & beverage$64,8624%
  • Education$720%
  • Other$41,4852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson363$547,586
Amgen603$478,393
Boehringer Ingelheim169$205,942
Bard Peripheral Vascular, Inc.140$127,115
Lilly USA, LLC99$124,106
Inari Medical, Inc.50$57,584
Angiodynamics, Inc.101$55,788
Cook Incorporated12$54,650
Lexicon Pharmaceuticals, Inc.48$38,934
Trireme Medical LLC10$36,935
Cardiovascular Systems Inc.50$32,443
Medalliance LLC4$27,600
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.11$26,682
Abbott16$25,309
Limflow Inc.17$20,328
Cook Research Incorporated8$16,940
Penumbra, Inc.63$15,895
Amarin Pharma, Inc.90$13,175
AstraZeneca25$12,536
Cook Medical LLC225$7,639
Cordis US CORP.4$3,680
Wilson Cook Medical Incorporated1$3,225
M.a. Med Alliance S.A.2$2,290
C. R. Bard, Inc. & Subsidiaries1$2,013
Merit Medical Systems Inc4$1,750
Boston Scientific31$1,492
Shockwave Medical, Inc14$1,080
W. L. Gore & Associates, Inc.5$1,065
Stryker7$670
Medtronic(2 entities)17$652
Novartis30$562
Endologix LLC2$550
Intact Vascular, Inc.4$402
E.r. Squibb & Sons, L.L.C.20$392
Pfizer22$356
Esperion Therapeutics, Inc.8$320
Abiomed3$286
CMS Imaging, Inc.3$272
Cvrx, Inc.5$234
Cardio Flow, Inc.2$218
Edwards Lifesciences1$212
Acist Medical Systems, Inc.4$204
Inspiremd Ltd3$203
Avinger Inc.2$193
Merck11$190
Philips North America LLC5$185
Innova Vascular Inc.1$160
Veryan Medical Incorporated1$150
Kestra Medical Technology Services, Inc.6$150
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$147
Celonova Biosciences, Inc.1$136
Venclose Inc.2$118
Novo Nordisk1$112
Bayer1$108
Kiniksa Pharmaceuticals, Ltd.5$97
Recor Medical Inc4$87
Organogenesis Inc.1$85
Opsens Inc.2$85
Siemens Medical Solutions USA, Inc.3$81
GE HealthCare2$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,950,355 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,039,514
Medicare patients
1,333
Services billed
5,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban293$243,183
EliquisApixaban254$226,030
EntrestoSacubitril/Valsartan185$182,996
JardianceEmpagliflozin207$151,805
Repatha SureclickEvolocumab112$94,660
Repatha PushtronexEvolocumab70$59,921
VascepaIcosapent Ethyl60$30,591
BrilintaTicagrelor38$20,483
Flecainide Acetate69$2,665
Metoprolol Succinate239$2,590
ClopidogrelClopidogrel Bisulfate251$2,229
Rosuvastatin Calcium200$2,074
Atorvastatin Calcium275$1,975
Isosorbide Mononitrate ErIsosorbide Mononitrate75$1,349
Carvedilol121$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$547,586$243,183293 claims
PfizerEliquis$356$226,030254 claims
NovartisEntresto$562$182,996185 claims
Boehringer IngelheimJardiance$205,942$151,805207 claims
AstraZenecaBrilinta$12,536$20,48338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →